Pharmaceuticals, Biotechnology and Life Sciences
XI’AN, China, April 08, 2025 (GLOBE NEWSWIRE) — Bon Natural Life Limited (Nasdaq: BON) (“BON” or “the Company”), a leading…
DUBLIN, April 08, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to…
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase…
Ipsen publishes its 2024 Universal Registration Document PARIS, FRANCE, 8 April 2025 – Ipsen (Euronext: IPN; ADR: IPSEY)…
–EFFICACY: 92% median reduction in disabling seizures during 7-12-month efficacy endpoint period, and 80% (4/5) of patients responding with >75%…
CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for neurodegenerative…
Las Vegas, Nevada, April 07, 2025 (GLOBE NEWSWIRE) — Tanke Biosciences Corp (the “Company”) (OTC: TNBI) announced today that John…
Auditor Licensing & Personnel Issues Delays Issuance of Audit OpinionThe Company expects to file within 1 week TORONTO, April 07,…
SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel…
Oncodesign Services has appointed Dr. Aidan Synnott as chief executive officer, to help strengthen its position as a trusted partner in drug discovery. The appointment reflects the company’s commitment to deepen client collaboration, enhance the quality of its science, and anticipate the evolving needs of the biopharma industry.